Toyohashi, Japan

Hideo Kato

This inventor holds 1 USPTO granted patent. Top assignee: Grelan Pharmaceutical Co., Ltd.. Active years: 2000.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Hideo Kato. Retrieved from https://idiyas.com/inventor/hideo-kato-86kdkh27

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Calculating rank

% Patents Active = 100.0

Average Co-Inventor Count = 4.0

ph-index = 1

Forward Citations = 7(Granted Patents)


Company Filing History:


Years Active: 2000

Loading Chart...
1 patent (USPTO):Explore Patents

Title: Hideo Kato: Innovator in Pharmaceutical Chemistry

Introduction

Hideo Kato is a notable inventor based in Toyohashi, Japan. He has made significant contributions to the field of pharmaceutical chemistry, particularly through his innovative work on pyrazole derivatives.

Latest Patents

Hideo Kato holds one patent titled "Pyrazole derivatives and COX inhibitors containing them." This patent showcases his expertise in developing compounds that have potential therapeutic applications.

Career Highlights

Kato is currently employed at Grelan Pharmaceutical Co., Ltd., where he continues to advance his research and development efforts. His work focuses on creating effective pharmaceutical solutions that address various health issues.

Collaborations

Hideo Kato collaborates with talented colleagues, including Tomoji Aotsuka and Nagatoshi Wagatsuma. Their combined efforts contribute to the innovative environment at Grelan Pharmaceutical Co., Ltd.

Conclusion

Hideo Kato's contributions to pharmaceutical chemistry through his patent and collaborative work highlight his role as an influential inventor in the industry. His ongoing research promises to lead to further advancements in medical science.

Profile summary based on public USPTO records.
Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]
Loading…